New partnership gives Bupa UK customers greater access to the latest cancer fighting technology

04 April 2018
woman with headscarf smiling
Bupa UK health insurance customers will have greater access to a new state-of-the-art cancer treatment within the next few weeks, thanks to a new partnership with the Proton Therapy Centre.

The Proton Therapy Center in Prague, Czech Republic uses the latest pencil-scanning technology to treat tumors and works by accelerating protons until they reach half the speed of light. 

Unlike traditional radiotherapy using X-rays, the proton therapy can pin-point the exact area to target, preserving healthy tissue around the tumour. This means the treatment is less invasive for the patient, and can help reduce their recovery time.

The technology has treated more than 2,500 patients from 25 countries.

Vaclav Lastovka, founder and CEO of the Proton Therapy Center, said: “We’re pleased to be working with Bupa to enable more patients with cancer to receive the benefit of this treatment.”

“Being a Bupa partner in the highly specialised field of oncological care is a great success for us. It is further confirmation that the results of our treatment and the quality of our medical services are recognised worldwide.”

Dr Tim Woodman, Bupa UK Medical Director said: “At Bupa we’re committed to providing our customers with access to fast, high quality healthcare that is right for them. 

“Our partnership with the Proton Therapy Center in Prague is another example of how we’re offering our customers better access to advanced cancer treatment.”

“For some very specific types of cancer, proton therapy has been shown to have distinct advantages over surgery or traditional radiotherapy and we are delighted to be able to offer our customers with these conditions a treatment that is designed to deliver better patient outcomes.”

Dr Jiri Kubes, Medical Director of the Proton Therapy Center, said: “The latest international studies on key cancer indications have shown that proton therapy is highly effective with minimal side effects. 

“The proton cancer treatment we offer enables both the improvement of the therapeutic results and the increased effectiveness of the treatment itself.” 

“By offering proton therapy, it means Bupa patients can not only have access to timely and effective treatment, but also the best possible quality of life after.”

During a trial of this new partnership Sylvia White, from Southampton UK was Bupa’s first customer to undergo the proton therapy after discovering a tumor behind her eye.

She said: “Thanks to the treatment I’m now cancer-free. I’m grateful for the highly professional medical care and excellent support that I received and I’m pleased that Bupa will continue to help and support other patients who can benefit from this remarkable technology.”

This treatment is available to eligible Bupa UK health insurance members. To check if you’re eligible, speak with the Bupa Oncology care team.  


 

About Bupa

Bupa's purpose is helping people live longer, healthier, happier lives.

With no shareholders, our customers are our focus. We reinvest profits into providing more and better healthcare for the benefit of current and future customers.

We have 15.5 million health insurance customers, provide healthcare to around 14.5 million people in our clinics and hospitals, and look after over 23,300 aged care residents.

We employ over 78,000 people, principally in the UK, Australia, Spain, Poland, Chile, New Zealand, Hong Kong, the USA, Brazil, the Middle East and Ireland, and many more through our associate businesses in Saudi Arabia and India.

Health insurance is around 70% of our business. In a number of countries, we also run clinics, dental centres, hospitals and care homes and villages.

For more information, visit www.bupa.com

 
Share this

Contact Bupa Press Office

If you're a journalist and would like to find out more about any of our activity, or request a comment from one of our spokespeople, please contact the Bupa Press Office via one of the below

ajax-loader